Last reviewed · How we verify
NCT00955773: Cancer
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
Phase 1 trial testing GSK1120212 plus everolimus in Cancer in 64 participants. Completed in 8 November 2011.
8 November 2011
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 17 August 2009 |
| Primary completion | 8 November 2011 |
| Estimated completion | 8 November 2011 |
| Sites | 3 locations across France, United States |
Drugs / interventions tested
- GSK1120212 plus everolimus — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. The escalation part of the study will determine the MTD. The combination will be further explored in the expansion part in subjects with metastatic pancreatic cancer. In addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
Collisson EA, Trejo CL, Silva JM, Gu S, et al · · 2012 · cited 252× · PMID 22628411 · DOI 10.1158/2159-8290.cd-11-0347 -
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, et al · · 2015 · cited 106× · PMID 25535693 · DOI 10.1097/jto.0000000000000405 -
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, et al · · 2015 · cited 106× · PMID 25344362 · DOI 10.1093/annonc/mdu482 -
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Conway JR, Herrmann D, Evans TJ, Morton JP, et al · · 2019 · cited 75× · PMID 30396902 · DOI 10.1136/gutjnl-2018-316822 -
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H, Zhou X, Fu D, Le C, et al · · 2023 · cited 19× · PMID 36316602 · DOI 10.1002/cac2.12377 -
Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.
Lee RP, Foster KA, Lillard JC, Klimo P, et al · · 2017 · cited 15× · PMID 28686121 · DOI 10.3171/2017.4.peds16668 -
Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS<sup>G12D</sup>-mutant pancreatic ductal adenocarcinoma.
Tan YQ, Sun B, Zhang X, Zhang S, et al · · 2024 · cited 6× · PMID 38409090 · DOI 10.1038/s41419-024-06551-7 -
Targeting <i>KRAS</i> in pancreatic adenocarcinoma: Progress in demystifying the holy grail.
Elhariri A, Alhaj A, Ahn D, Sonbol MB, et al · · 2023 · cited 5× · PMID 37700806 · DOI 10.5306/wjco.v14.i8.285
Verify or expand the search:
- PubMed search for NCT00955773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00955773 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 9 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00955773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing